Givaudan is revamping product development across its beauty and fragrance divisions as weight loss treatments reshape consumer budgets, tracked by 15 generic semaglutide brands entering India since patent expirations began. The ingredient supplier found adult adoption of GLP-1 therapies in the US climbed from 3 per cent in 2024 to 11 per cent in 2026, triggering direct reallocation of discretionary spending.

Data compiled by the manufacturer from a NielsenIQ Homescan panel revealed American households using the medications increased spending on fine fragrances by 97 per cent while cutting grocery budgets. In Brazil, 47 per cent of buyers reported trimming other expenses specifically to finance treatment doses, signaling a widespread behavioral reallocation away from food toward personal grooming, sports, and travel.

Price reductions and the loss of patent exclusivity in markets such as India have dismantled entry barriers for metabolic therapies. The introduction of 15 domestic brands following patent expiries expanded regional supply rapidly, lowering therapy costs and broadening usage beyond narrow clinical segments.

Lower retail prices combined with the development of oral alternatives to subcutaneous injections are speeding up adoption across emerging economies. For personal care brands operating in Asia, this shift alters the customer base faster than anticipated. Product developers must adjust formulas for consumers managing the physiological consequences of rapid weight reduction.

Patients experience specific physiological issues that prompt new topical requirements, notably loss of facial volume, loose skin, barrier dryness, temporary hair thinning, and bad breath. Consumers navigating these side effects prioritize demonstrable performance over brand prestige, checking active concentrations and clinical validation closely.

Source link